Thrombin inhib 
Welcome,         Profile    Billing    Logout  
 10 Companies  11 Products   11 Products   67 Diseases   197 Trials   6615 News 


12345678910111213...2627»
  • ||||||||||  aspirin / Generic mfg.
    Review, Journal:  Optimal antithrombotic strategy following valve-in-valve transcatheter aortic and mitral valve replacement. (Pubmed Central) -  Mar 20, 2024   
    Although the recommended antithrombotic strategy for native transcatheter aortic valve replacement (TAVR) is antiplatelet monotherapy with aspirin or a P2Y12 inhibitor in the absence of another anticoagulation indication, the use of oral anticoagulants including vitamin K antagonists (VKAs) and direct thrombin inhibitors has been shown to be effective in reducing valvular thrombosis and are commonly used after ViV procedures. Prospective studies investigating these results specifically for ViV transcatheter aortic and mitral valve replacement are needed to identify the optimal antithrombotic therapy.
  • ||||||||||  Review, Journal:  Hirudin in the Treatment of Chronic Kidney Disease. (Pubmed Central) -  Mar 17, 2024   
    The mechanisms of hirudin in treating CKD are mainly related to inhibiting the inflammatory response, preventing apoptosis of intrinsic renal cells, and inhibiting the interactions between thrombin and protease-activated receptors. In this review, we summarize the function and beneficial properties of hirudin for the treatment of CKD, and its underlying mechanisms.
  • ||||||||||  Single-stranded short tandem repeats bind thrombin in neutrophil extracellular traps (In-person; Room 356 (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_12337;    
    Our identification of this ssSTR-mediated thrombin binding extended the current understanding of the mechanism of NET-promoted coagulation and diseases-associated thrombosis and provided a potential therapeutic target for coagulation disorders. Importantly, we reveal a unique sequence-dependent ssDNA-protein interaction, expanding the understanding of genomic non-coding ssDNAs' roles in biological processes.
  • ||||||||||  Journal:  New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants. (Pubmed Central) -  Mar 11, 2024   
    In summary, this study introduces novel triazole-based small molecules, specifically compounds 8 and 22, identified as potent and selective inhibitors of human FXIIa. The aim is to advance these inhibitors for further development as anticoagulants to provide a more effective and safer approach to preventing and/or treating thromboembolic diseases.
  • ||||||||||  Review, Journal:  Between a (Pubmed Central) -  Mar 8, 2024   
    The aim is to advance these inhibitors for further development as anticoagulants to provide a more effective and safer approach to preventing and/or treating thromboembolic diseases. Until then, a
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal:  Development of a Rapid Qualitative Screen for Anticoagulant Presence. (Pubmed Central) -  Mar 4, 2024   
    No abstract available Our study demonstrates that commonly available heparin anti-Xa activity and TT assays can be used to qualitatively detect DOACs and fondaparinux and provides a method to establish a qualitative interpretation.
  • ||||||||||  Journal:  Phototriggered Equilibrated and Transient Orthogonally Operating Constitutional Dynamic Networks Guiding Biocatalytic Cascades. (Pubmed Central) -  Feb 29, 2024   
    Also, the photogenerated CDN was applied to control the reconfiguration of coupled CDNs, leading to upregulated/downregulated formation of the antithrombin aptamer units, resulting in the dictated inhibition of thrombin activity (fibrinogen coagulation). Moreover, a reaction module consisting of GOx/HRP-modified o-nitrobenzyl phosphate-caged DNA hairpins, photoresponsive caged auxiliary duplexes, and nickase leads upon irradiation to the emergence of a transient, dissipative CDN activating in the presence of two alternate auxiliary triggers, achieving transient operation of up- and downregulated GOx/HRP biocatalytic cascades.
  • ||||||||||  dabigatran etexilate / Generic mfg.
    Massive Hemoptysis Preceded by Dabigatran in a Patient With Bronchiectasis (TDP38) -  Feb 20, 2024 - Abstract #ATS2024ATS_6178;    
    He subsequently received a 5 g bolus of idarucizumab...He subsequently received fresh frozen plasma and tranexamic acid...Our case builds upon this limited literature, and further suggests that patients with bronchiectasis may need thorough evaluation and risk stratification of bleeding before initiating dabigatran. Future studies help identify whether patients with bronchiectasis are at greater risk of massive hemoptysis when initiated on dabigatran.
  • ||||||||||  Gen-1124 / GEn1E Lifesci
    Novel Next-generation Non-catalytic P38alpha/MK2 Immunomodulators With Endothelial-barrier-stabilizing and Anti-inflammatory Activity (TDP04) -  Feb 20, 2024 - Abstract #ATS2024ATS_3457;    
    A next-generation analog with modifications on the first and third ring, GEn1124, has improved anti-inflammatory and endothelial barrier-stabilizing activity, is lung protective in mouse models of influenza and ARDS, and is currently in a Phase II clinical trial in ARDS... We have developed two novel next-generation analogs of the noncatalytic p38akpha/MK2 inhibitor UM101 that demonstrate anti-inflammatory actions and endothelial barrier-stabilizing activity greater than the parent compound.
  • ||||||||||  INBRX-101 / Inhibrx
    Protease Inhibitory Specificity Profile of the Recombinant Human Alpha-1 Antitrypsin (AAT)-Fc Fusion Protein INBRX-101 (San Diego Convention Center, Room 33A-C (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_828;    
    P1, P2
    Modifications to extend the half-life of INBRX-101 did not lead to off-target activity against thrombin or trypsin. INBRX-101 is currently being evaluated in ElevAATe (NCT05856331), a registration-enabling phase 2 randomized trial in patients with AATD that will compare INBRX-101 vs pdAAT and their impact on functional AAT levels.
  • ||||||||||  argatroban / Generic mfg.
    Retrospective data, Review, Journal:  Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis. (Pubmed Central) -  Feb 5, 2024   
    Compared to KRAS wild-type colorectal cancer cells, KRAS-mutant colorectal cancer cell lines were more likely to be hypercoagulable through the upregulation of thrombin expression, which was mainly achieved through the TF-thrombin pathway. Argatroban did not significantly increase the risk of adverse events or symptomatic intracranial hemorrhage (ICH), or major systemic bleeding compared to control or r-TPA (p
  • ||||||||||  707. Stop the Clot: Anticoagulation in Congenital Heart Disease (B308) -  Jan 26, 2024 - Abstract #ACC2024ACC_5999;    
    DESCRIPTION Do you struggle to make sense of anticoagulation and antiplatelet data, especially as they apply to the congenital heart patient? Join us as we tackle a walk through current data, indications, contraindications, and applicaiton of NOACs, direct thrombin inhibitors, and antiplatelet management in CHD.
  • ||||||||||  Review, Journal:  How to Ensure Patency of the Extracorporeal Circuit in Hemodialysis: Global Perspectives. (Pubmed Central) -  Jan 25, 2024   
    Classical anticoagulants are still the standard of anticoagulation, but many questions remain unanswered; for example, is there real superiority of one treatment over another in terms of efficacy, safety, and health care economics? Anticoagulant protocols for hemodialysis need to be standardized and further studies performed to answer all of these questions.
  • ||||||||||  argatroban / Generic mfg.
    Clinical, Retrospective data, Review, Journal:  Argatroban as an Add-On to rtPA in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jan 23, 2024   
    Analysis of risk ratio and relative risk shows that the add-on therapy with argatroban seems to be effective and favors a good clinical outcome (mRS 0-2) at 90 days, similar to that of alteplase...Argatroban as an add-on treatment to IVT seems not to be associated with excessive bleeding risk; however, its efficacy remains unproven. According to this synopsis of the currently available evidence, it is premature to use argatroban as an add-on to IVT treatment outside the current clinical trial setting.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Andexanet (Pubmed Central) -  Jan 22, 2024   
    According to this synopsis of the currently available evidence, it is premature to use argatroban as an add-on to IVT treatment outside the current clinical trial setting. This study in
  • ||||||||||  Journal:  New anticoagulant protein from medicinal leech. (Pubmed Central) -  Jan 20, 2024   
    The recombinant protein was expressed in E. coli. This protein is capable of directly inhibiting thrombin, and based on indirect evidence, other proteases of the blood coagulation cascade have been identified.
  • ||||||||||  Journal:  HEPARIN-INDUCED THROMBOCYTOPENIA SYNDROME AMONG HEMODIALYSIS PATIENTS AND DISEASE MANAGEMENT STRATEGY. (Pubmed Central) -  Jan 18, 2024   
    This study used two cases from two patients who suffer from HD-HIT, and it concluded that it is necessary to diagnose heparin-induced thrombocytopenia syndrome as soon as possible, as it may lead to a high rate of infections and deaths if left untreated since dialysis patients are frequently exposed to heparin. Their condition may lead to moderate thrombocytopenia.
  • ||||||||||  Journal:  Discovering peptide inhibitors of thrombin as a strategy for anticoagulation. (Pubmed Central) -  Jan 16, 2024   
    In vitro anti-platelet aggregation assay was carried out, suggesting the 3 peptides can inhibit the platelet aggregation induced by thrombin. This study showed computer-aided peptide inhibitor design can be a robust method for finding potential binders for thrombin, which provided solutions for anticoagulation.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    PK/PD data, Review, Journal:  Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. (Pubmed Central) -  Jan 15, 2024   
    In order to give an appropriate dose of DOAC drugs, accurate estimation of renal function using the Cockcroft-Gault formula using actual body weight is necessary. An increasing body of evidence supports the use of DOACs in patients who are obese, and this is becoming more routine in clinical practice.
  • ||||||||||  bivalirudin / Generic mfg.
    Management of HIT Prior to Heart Transplant on Temporary MCS (Poster Hall) -  Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1771;    
    Confirmed HIT presents challenges in cardiac surgery which often requires heparin administration. Non-heparin anticoagulants, such as bivalirudin, plasmapheresis, and IVIG show promising results in clinical and surgical management of HIT patients supported with tMCS undergoing heart transplant.
  • ||||||||||  dabigatran etexilate / Generic mfg.
    Preclinical, Journal:  Preclinical Study on a Novel Fluoroderivative of Dabigatran Etexilate in Animal Models. (Pubmed Central) -  Jan 8, 2024   
    Another safety assessment of R1 indicated that there were no risks of acute poisoning in rats and cardiac toxicity in mice or rats. Therefore, R1 can be considered a new candidate anticoagulant compound with great potential and significance for further clinical research.
  • ||||||||||  bivalirudin / Generic mfg.
    EFFECT OF HYPERBILIRUBINEMIA AND PLASMA EXCHANGE ON ANTICOAGULATION WITH UNFRACTIONATED HEPARIN () -  Jan 4, 2024 - Abstract #SCCM2024SCCM_1223;    
    The patient was initially on bivalirudin, but imaging on ECMO day seven showed unchanged clot burden with one new subsegmental PE...However, TPE itself has also been known to interfere with both anti-Xa and aPTT monitoring. Ultimately, an ACT-guided approach was successfully utilized to manage UFH without complications.
  • ||||||||||  bivalirudin / Generic mfg., argatroban / Generic mfg.
    USE OF DILUTE THROMBIN TIME FOR DIRECT THROMBIN INHIBITOR MONITORING AT AN ACADEMIC MEDICAL CENTER () -  Jan 4, 2024 - Abstract #SCCM2024SCCM_1210;    
    Targeting the standard aPTT goal to monitor DTIs in these patients may result in subtherapeutic levels of anticoagulation. Utilizing the dTT to create custom aPTT goals and titrations for patients presenting with elevated aPTTs at baseline appears to provide adequate levels of anticoagulation with minimal safety concerns.
  • ||||||||||  bivalirudin / Generic mfg.
    Journal:  Bivalirudin-hydrogel coatings of polyvinyl chloride on extracorporeal membrane oxygenation for anticoagulation. (Pubmed Central) -  Jan 3, 2024   
    The systemic anticoagulant assay proved that BV hydrogel coating does not affect the coagulation level, and reduces the risk of complications such as systemic bleeding compared to intravenous injection. BV-Coating GelMA hydrogel tube has exhibited good biocompatibility and significantly improved anticoagulant performance, making it an optimal choice for surface materials used in blood-contacting medical devices.
  • ||||||||||  Review, Journal:  Stroke Prevention in Atrial Fibrillation: Our Current Failures and Required Research. (Pubmed Central) -  Dec 26, 2023   
    A direct thrombin inhibitor, factor Xa inhibitors, and left atrial appendage closure are FDA-approved approaches whereas factor XIa inhibitors are currently being studied in phase 3 randomized controlled trials for stroke prevention. The benefits, risks, and shortcomings of these treatments and future research required in different high-risk patient populations are reviewed in this consensus statement.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Management of Bleeding due to Anticoagulants (North-122) -  Dec 24, 2023 - Abstract #SCCM2024SCCM_359;    
    This lecture will discuss evidence based reversal of medications such as: warfarin, oral anti-Xa inhibitors (DOACS - apixaban, rivaroxaban, etc.), subcutaneous anti-Xa inhibitors (enoxaparin), direct thrombin inhibitors (argatroban, bivalirudin). The use of plasma, prothrombin complex concentrates and specific antidotes (andexanet alfa) will be discussed, reviewed with risks and benefits of each.
  • ||||||||||  Journal, Adverse events:  Association of antidepressants plus antithrombotics and bleeding risk: a pharmacovigilance study. (Pubmed Central) -  Dec 19, 2023   
    The use of plasma, prothrombin complex concentrates and specific antidotes (andexanet alfa) will be discussed, reviewed with risks and benefits of each. The present study suggests an increased risk of "serious" bleeding when SRIs (but not NSMRIs) are associated with antithrombotics (all antithrombotics and not only DOACs).